Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01587001 · ClinicalTrials.gov registry record · NA
The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
A NA study of Pulmonary Sarcoidosis, sponsored by National Jewish Health.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT01587001 is a NA study of Pulmonary Sarcoidosis that has completed, run by National Jewish Health. The registered enrollment target is 17 participants, below the 812-participant average among 5 other Pulmonary Sarcoidosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01587001, a NA study of Pulmonary Sarcoidosis, has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study investigating the effect of an antioxidant, N-Acetyl-L-Cysteine (NAC), on inflammation and oxidative stress in sarcoidosis.
Conditions Studied
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT N-acetyl-cysteine
Study Locations (1)
Colorado
- National Jewish Health - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01587001
The ClinicalTrials.gov registry entry for NCT01587001 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 812-participant average among 5 other Pulmonary Sarcoidosis trials with a reported enrollment target (98% lower). The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Sarcoidosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01587001 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT01587001 about?
NCT01587001 is a clinical study titled "The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis". This is a pilot study investigating the effect of an antioxidant, N-Acetyl-L-Cysteine (NAC), on inflammation and oxidative stress in sarcoidosis.
What is the current status of trial NCT01587001?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2011-11. Estimated completion is 2014-10.
What conditions does trial NCT01587001 study?
This clinical trial studies the following conditions: Pulmonary Sarcoidosis.
What interventions are being tested in trial NCT01587001?
The interventions under investigation include: Placebo (DRUG), N-acetyl-cysteine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01587001?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01587001 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Sarcoidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
RECRUITING · Phase 1
-
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
RECRUITING · Phase 2
-
Role of Genetic Factors in the Development of Lung Disease
RECRUITING
-
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
ACTIVE NOT RECRUITING · Phase 3
-
Treatment of Pulmonary Sarcoidosis With Pentoxifylline
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.